Cargando…

(18)F-florbetapir PET/MRI for quantitatively monitoring myelin loss and recovery in patients with multiple sclerosis: A longitudinal study

BACKGROUND: Amyloid positron emission tomography (PET) can measure in-vivo demyelination in patients with multiple sclerosis (MS). However, the value of (18)F-labeled amyloid PET tracer, (18)F-florbetapir in the longitudinal study for monitoring myelin loss and recovery has not been confirmed. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Min, Ni, You, Zhou, Qinming, He, Lu, Meng, Huanyu, Gao, Yining, Huang, Xinyun, Meng, Hongping, Li, Peihan, Chen, Meidi, Wang, Danni, Hu, Jingyi, Huang, Qiu, Li, Yao, Chauveau, Fabien, Li, Biao, Chen, Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234356/ https://www.ncbi.nlm.nih.gov/pubmed/34195586 http://dx.doi.org/10.1016/j.eclinm.2021.100982

Ejemplares similares

Hybrid (18)F-florbetapir PET/MRI for assessing myelin recovery in GFAP-A patients
por: Meng, Huanyu, et al.
Publicado: (2022)

Characteristics of cerebral blood flow in an Eastern sample of multiple sclerosis patients: A potential quantitative imaging marker associated with disease severity
por: Zhou, Qinming, et al.
Publicado: (2022)

(18)F-florbetapir PET as a marker of myelin integrity across the Alzheimer’s disease spectrum
por: Moscoso, Alexis, et al.
Publicado: (2021)

(18)F-florbetapir PET/MRI for quantitatively monitoring demyelination and remyelination in acute disseminated encephalomyelitis
por: Zhang, Min, et al.
Publicado: (2019)

[(18)F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis
por: Carotenuto, Antonio, et al.
Publicado: (2019)

A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?
por: Xu, Xiaojiao, et al.
Publicado: (2021)

Operationalizing the centiloid scale for [(18)F]florbetapir PET studies on PET/MRI
por: Coath, William, et al.
Publicado: (2023)

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2014)

Cortical florbetapir-PET amyloid load in prodromal Alzheimer’s disease patients
por: Saint-Aubert, Laure, et al.
Publicado: (2013)

FoxP3(−) Tr1 Cell in Generalized Myasthenia Gravis and Its Relationship With the Anti-AChR Antibody and Immunomodulatory Cytokines
por: Meng, Huanyu, et al.
Publicado: (2021)

Performance of Multiparametric Functional Imaging and Texture Analysis in Predicting Synchronous Metastatic Disease in Pancreatic Ductal Adenocarcinoma Patients by Hybrid PET/MR: Initial Experience
por: Gao, Jing, et al.
Publicado: (2020)

Multi-contrast attenuation map synthesis for PET/MR scanners: assessment on FDG and Florbetapir PET tracers
por: Burgos, Ninon, et al.
Publicado: (2015)

Florbetapir Regional Distribution in Cerebral Amyloid Angiopathy and Alzheimer’s Disease: A PET Study
por: Planton, Mélanie, et al.
Publicado: (2020)

Radiation dosimetry of florbetapir F 18
por: Joshi, Abhinay D, et al.
Publicado: (2014)

APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study
por: Ramanan, Vijay K., et al.
Publicado: (2013)

Paraneoplastic Amyotrophic Lateral Sclerosis: Case Series and Literature Review
por: Yang, Zhao, et al.
Publicado: (2022)

Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study
por: Doraiswamy, P M, et al.
Publicado: (2014)

PET imaging of 18F-florbetapir in cognitively impaired individuals: Lack of activity within the cerebellar cortex
por: Meyer, Michael A., et al.
Publicado: (2018)

Dual-phase [18F]florbetapir in frontotemporal dementia
por: Asghar, Michael, et al.
Publicado: (2018)

Combined quantitative T2 mapping and [(18)F]FDG PET could improve lateralization of mesial temporal lobe epilepsy
por: Zhang, Miao, et al.
Publicado: (2022)

Using PET with (18)F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment
por: Camus, V., et al.
Publicado: (2012)

A Routine PET/CT Protocol with Streamlined Calculations for Assessing Cardiac Amyloidosis Using (18)F-Florbetapir
por: Osborne, Dustin R., et al.
Publicado: (2015)

Plasma Aβ analysis using magnetically-labeled immunoassays and PET (18)F-florbetapir binding in non-demented patients with major depressive disorder
por: Wu, Kuan-Yi, et al.
Publicado: (2018)

Myelin positron emission tomography (PET) imaging in multiple sclerosis
por: de Paula Faria, Daniele
Publicado: (2020)

Evaluation of Myelin Radiotracers in the Lysolecithin Rat Model of Focal Demyelination: Beware of Pitfalls!
por: Zhang, Min, et al.
Publicado: (2019)

Simultaneous PET/fMRI Detects Distinctive Alterations in Functional Connectivity and Glucose Metabolism of Precuneus Subregions in Alzheimer’s Disease
por: Zhang, Miao, et al.
Publicado: (2021)

Author Correction: Plasma Aβ analysis using magnetically-labeled immunoassays and PET (18)F-florbetapir binding in non-demented patients with major depressive disorder
por: Wu, Kuan-Yi, et al.
Publicado: (2019)

Immune Checkpoint Inhibitor Associated Autoimmune Encephalitis, Rare and Novel Topic of Neuroimmunology: A Case Report and Review of the Literature
por: Gao, Yining, et al.
Publicado: (2022)

Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo
por: Saint-Aubert, L., et al.
Publicado: (2013)

Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies
por: Su, Yi, et al.
Publicado: (2019)

Pilot Study of F18-Florbetapir in the Early Evaluation of Cardiac Amyloidosis
por: Sperry, Brett W., et al.
Publicado: (2021)

The value of (18)F-fluorodeoxyglucose positron emission tomography/magnetic resonance whole-body scans and local enhancement scans in the preoperative staging and resectability assessment of pancreatic adenocarcinoma
por: Wang, Weishen, et al.
Publicado: (2023)

A consecutive case series experience with [(18) F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition
por: Mitsis, Effie M, et al.
Publicado: (2014)

Clinical impact of amyloid PET using (18)F-florbetapir in patients with cognitive impairment and suspected Alzheimer’s disease: a multicenter study
por: Matsuda, Hiroshi, et al.
Publicado: (2022)

Performance of (18)F-FDG PET/CT Radiomics for Predicting EGFR Mutation Status in Patients With Non-Small Cell Lung Cancer
por: Zhang, Min, et al.
Publicado: (2020)

PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with (18)F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders
por: Siderowf, Andrew, et al.
Publicado: (2014)

Disrupted coupling between salience network segregation and glucose metabolism is associated with cognitive decline in Alzheimer's disease – A simultaneous resting-state FDG-PET/fMRI study
por: Zhang, Miao, et al.
Publicado: (2022)

[(68)Ga]Ga-DOTA-FAPI-04 PET/MR in patients with acute myocardial infarction: potential role of predicting left ventricular remodeling
por: Zhang, Min, et al.
Publicado: (2022)

Tracer‐specific reference tissues selection improves detection of (18)F‐FDG, (18)F‐florbetapir, and (18)F‐flortaucipir PET SUVR changes in Alzheimer's disease
por: Li, Yanxiao, et al.
Publicado: (2022)

Classification of negative and positive (18)F-florbetapir brain PET studies in subjective cognitive decline patients using a convolutional neural network
por: de Vries, Bart Marius, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vc2ilkad8d59jqerslbasotdsi